CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $81 to $165, according to analysts polled by Capital IQ....
Health care stocks traded above their earlier lows this afternoon, with the NYSE Health Care Index falling 0.7% while the SPDR Health Care Select Sector...
Health care stocks traded above their earlier lows this afternoon, with the NYSE Health Care Index falling 0.7% while the SPDR Health Care Select Sector...
Health care stocks were flat to lower pre-bell Tuesday. The iShares NASDAQ Biotechnology Index (IBB) was inactive while the Health Care SPDR (XLV) was down...
Health care stocks were flat to lower pre-bell Tuesday. The iShares NASDAQ Biotechnology Index (IBB) was inactive while the Health Care SPDR (XLV) was down...
BioMarin Pharmaceutical (BMRN) said Sunday that the US Food and Drug Administration has placed its phase 1/2 trial of BMN 307 gene therapy in adults with...
BioMarin Pharmaceutical (BMRN) has an average rating of outperform and price targets ranging from $81 to $165, according to analysts polled by Capital IQ....
BioMarin Pharmaceutical (BMRN) said the European Commission has granted marketing authorization for Voxzogo to treat achondroplasia in children. The...
George Eric Davis, EVP, General Counsel, reported a sale of 5,518 shares in BioMarin Pharmaceuticals (BMRN) on Aug 02, 2021, for $423,175. Davis,...